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The crystal structure of the telomeric sequence d(UBrAGG) interacting with an
anthraquinone derivative has been solved by MAD. In all previously studied
complexes of intercalating drugs, the drug is usually sandwiched between two
DNA base pairs. Instead, the present structure looks like a crystal of stacked
anthraquinone molecules in which isolated base pairs are intercalated. Unusual
base pairs are present in the structure, such as GG and AUBr reverse Watson–
Crick base pairs.
1. Introduction
There is presently great interest in drugs which may interact with G4
quadruplexes and thus interfere with telomere function. We have
therefore attempted the cocrystallization of several peptide deriva-
tives of anthraquinone and acridine drugs with the oligonucleotide
d(TAGG) and its related sequence d(UBrAGG), which is part of the
human telomere sequence. In solution, it appears that this oligo-
nucleotide may form guanine tetrads as determined by NMR
(Kettani et al., 1997). We have obtained adequate cocrystals with the
drug N,N0-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)-bis-N2,N2-
dimethylglycinamide, the structure of which is shown in Fig. 1.
The crystal structure that we have obtained is most unusual and
unexpected. It does not contain any guanine tetrads, only guanine–
guanine base pairs. It shows stacks of drug molecules in which some
unusual base pairs are intercalated. We may think of this structure as
DNA intercalated in a drug crystal, rather than the usual intercala-
tion of a drug in a DNA duplex.
We should also note that there are very few previous studies of
DNA–anthraquinone complexes. Gasper et al. (1998) determined the
structure for an anthraquinone with a single side chain, which showed
# 2010 International Union of Crystallography
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Figure 1
(a) Chemical structure of N,N0-(9,10-dioxo-9,10-dihydroanthracene-2,7-diyl)-bis-
N2,N2-dimethylglycinamide. For refinement, the terminal dimethylamino groups
were removed. An OMIT electron-density map (Fo  Fc at the 2 level) of one of
the drugs (E) and one associated water molecule is also shown (b).
a standard intercalation. In contrast, anthraquinones with two side
chains show unusual stacking features and significant disorder (Yang
et al., 2000; Valls et al., 2005).
In addition to the interest of this study in order to understand
DNA–drug interactions, its unusual features may be helpful in the
design of DNA nanostructures, a field that is currently under strong
development.
2. Experimental
The anthraquinone drug (Fig. 1) was a gift from Professor S. Neidle. It
was obtained using methods that are described elsewhere (Zagotto et
al., 2008). The drug was crystallized in association with the tetra-
nucleotide dUBr-dA-dG-dG. Crystals were obtained at 310 K in
hanging drops (5 ml) using the following conditions: 0.8 mM DNA,
1.6 mM drug, 22 mM sodium cacodylate pH 7.0, 15 mM NaCl,
0.8 mM MgCl2, 20% PEG 400. The reservoir contained 1 ml crys-
tallization solution with a higher concentration of PEG 400. X-ray
diffraction data were measured with cryocooling at 110 K on the
former Spanish beamline BM14 at the European Synchrotron
Radiation Facility. Data were measured from different crystals. Data
from crystal 1 were collected at a wavelength of 0.9795 A˚; it diffracted
to a maximum resolution of 2.4 A˚. However, only data to 2.8 A˚
resolution could be used owing to increased mosaicity in the higher
resolution region. Data from crystal 2 were collected to 3.0 A˚
resolution at three different wavelengths in order to use multiple-
wavelength anomalous dispersion (MAD) with bromine as the heavy
atom. The wavelengths used were obtained from a fluorescence
spectrum measured from the crystal. The data were integrated and
scaled with the HKL suite (Otwinowski & Minor, 1997). A mosaicity
of 0.7–1.2 was found. The space group turned out to be tetragonal
P43212, with unit-cell parameters a = b = 29.7, c = 60.88 A˚. Initial
phases were obtained by MAD using the program CNS (Bru¨nger et
al., 1998). Two Br atoms were detected. The model was manually built
and the anthraquinones were inserted into the electron density. The
model was then refined using the MAD phases with the CNS package
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Figure 2
Stereoviews of (a) the asymmetric unit and (b) the electron-density map (2Fo  Fc at the 1.2 level) of one portion of the structure. The anthraquinone molecules correspond
to C, D, E and F from top to bottom, as shown schematically in Fig. 4. Chain A is in the upper part, with chain B below. In the electron-density map one symmetry-related UBr
base is also shown. It forms a reverse Watson–Crick base pair with the adenine of chain A. Note that the two DNA molecules in the asymmetric unit have a practically
identical conformation, with the exception of the UBr residue. One magnesium ion (pink) with four coordinated water molecules (red) is also shown.
Table 1
Crystal data and refinement statistics.
Values in parentheses are for the last shell.
Wavelength (A˚) 0.907
Temperature (K) 110
Space group P43212
Unit-cell parameters (A˚, ) a = b = 29.70, c = 60.88,  =  =  = 90
Resolution range (A˚) 28–2.8 (2.875–2.803)
Unique reflections 757
Free R factor reflections 41
Completeness (%) 99.01 (100)
Redundancy factor 8.9
Rmerge† 0.060
Contents of asymmetric unit 2 DNA single chains, 3.5 anthraquinones,
1 magnesium, 6 water molecules
Rwork‡ 0.232 (0.430)
Rfree‡ 0.259 (0.164)
Mean B factors (A˚2)
Wilson plot 48.9
DNA 44.1
Anthraquinone C 112.1
Anthraquinone D 81.6
Anthraquinone E 46.6
Anthraquinone F 35.3
Magnesium ion 94.0
Water molecules 101.8
R.m.s.d. bonds (A˚) 0.006
R.m.s.d. angles () 1.769
R.m.s.d. chiral (A˚3) 0.059
† Rmerge(I) =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ calculated for the whole data
set. ‡ Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj. Rfree is the R factor calculated for
reflections used for cross-validation during refinement.
(Bru¨nger et al., 1998). Refinement was concluded with REFMAC5
(Murshudov et al., 1997) using data to 2.8 A˚ resolution. We used the
standard dictionary found in LIBCHECK from the CCP4 interface.
Rigid-body refinement of B factors was performed using a single TLS
group. The side chains of the drug were disordered and were partially
eliminated for refinement, as shown in Fig. 1. The asymmetric unit
and the electron-density map for one portion of it are presented in
Fig. 2. Data-set and refinement statistics are shown in Table 1. Note
that the Rfree value in the last shell is very low. This anomaly was a
consequence of the fact that only three reflections were used in order
to calculate this value.
The position of the plane of the drugs was clearly defined as shown
in Fig. 3. However, the side chains could not be located. A 180
rotation of the drug molecules around their main axis did not change
their R factors. It appears that the drug molecules may have multiple
positions in their average plane which prevent localization of the side
chains. This fact is apparent from the large B factors of the drug
molecules, as given in Table 1. Anthraquinone F sits on a dyad axis
and was modelled with 50% occupancy. The two superimposed
symmetric drugs in the same plane had their side chains in opposite
orientations. As a result, their B factors (Table 1) are significantly
smaller. It should also be noted that the exact position of a related
anthraquinone drug studied at much higher resolution could not be
accurately modelled (Valls et al., 2005).
Attempts to model residual electron density in the neighbourhood
of the anthraquinones did not help to locate the side chains. A
significant region of missing electron density was found next to
anthraquinone C, but the side chains could not be traced. A tentative
magnesium ion was instead placed in this region, with four associated
water molecules in an approximately octahedral coordination. Co-
ordination was completed by an O atom from anthraquinone C and a
phosphate O atom from a neighbouring asymmetric unit. However,
their B factors were high, as shown in Table 1.
3. Results and discussion
This oligonucleotide has a partial sequence of human telomere repeat
motifs. It has previously been studied by NMR (Kettani et al., 1997)
and formed a guanine tetrad. Therefore, we thought that it would be a
good model in order to study the interaction of anthraquinone drugs
with telomere sequences. Instead, we found a complex structure in
which several anthraquinone molecules are stacked together with
several base pairs, as shown in Fig. 4. The asymmetric unit of this
structure contains three and a half anthraquinone molecules and two
oligonucleotide chains (Fig. 2). The DNA bases form guanine–
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Figure 3
Stereoview of the electron-density map (2Fo  Fc at the 1.2 level) of the central anthraquinone F with its two neighbouring anthraquinones E. The figure illustrates that the
planes of the drugs are clearly defined, although the side chains could not be located.
Figure 4
In the crystal the drugs (blue) are stacked together with G3G3 (red) and AUBr
base pairs (yellow). They form infinite columns, with neighbouring columns
perpendicular to the plane of the figure. The codes for each base and drug (ANQ)
are shown on the right. Each individual d(UBrAGG) molecule is shared by two
perpendicular columns in the crystal, with the guanines in one column and the
UBrA bases in a perpendicular column.
guanine, standard adenine–thymine and reverse adenine–thymine
Watson–Crick base pairs. They are stacked among the anthraquinone
residues. The plane of the anthraquinone drugs is clearly defined
(Fig. 3), but the positions of the side chains could not be ascertained.
The column of stacked anthraquinone/base pairs presents several
dyad axes. Guanine 4 forms an independent group of stacked bases
which lie outside the stacked columns, as indicated in Fig. 4. They
interact through hydrogen bonds with the AT base pairs in neigh-
bouring stacked columns, as shown in Fig. 2. In the crystal, parallel
sets of columns are surrounded by symmetry-related identical
perpendicular columns. This work demonstrates that short oligo-
nucleotides may adopt quite unexpected shapes. This structure
contains several unusual features that are not found in longer
oligonucleotides.
The DNA bases in the structure present hydrogen bonds that are
not frequently found. Guanine 3 forms a base pair through hydrogen
bonding of the N2 and N3 atoms, as shown in Fig. 5. Such an inter-
action is not found in guanine crystals (Thewalt et al., 1971) or in
guanine tetrads. However, it is present in the standard crystal struc-
ture of DNA dodecamers (Dickerson et al., 1987). The guanine 3 base
pair is further stabilized through hydrogen bonds with phosphate O
atoms. Adenines and thymines in the present structure form an
unusual stack of base pairs, as is also shown in Fig. 5. The two central
base pairs form a reverse Watson–Crick system of hydrogen bonds.
The other two AT base pairs have standard Watson–Crick hydrogen
bonds.
We have compared our structure with those found in some
anthraquinone-derivative crystals available in the Cambridge Struc-
tural Database (Allen, 2002). The structure is strongly influenced by
the size and polarity of the side chains attached to the anthraquinone
rings. In general, anthraquinones with small lateral side chains pack
as infinite stacked columns that are usually slanted (Kingsford-
Adaboh & Kashino, 1995; Il’in et al., 1975; Janczak, 1995; Fu & Brock,
1998), similar to the situation found here in anthraquinones E and F
(Figs. 3 and 4). In some cases the inclination is very large (Popova et
al., 1975). In one case (de Ruyck et al., 2006), although the side chains
are small (two OH groups), the anthraquinone molecules are stacked
in an approximate perpendicular fashion, as found here in anthra-
quinones C and D (Fig. 4). Cases of staggered stacking are also found
(de Abreu et al., 2002). Finally, in the presence of bulky side chains no
stacking is found (Agbandje et al., 1992). In summary, the variability
of stacking features present in our structure is reminiscent of that
found in crystals of anthraquinone derivatives. Drawings of all
stacking pairs in our structure are available in De Luchi (2008).
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Figure 5
The DNA base pairs in the structure. G3G3 pairs are shown in (a). AUBr pairs are shown in (b) and are reverse Watson–Crick in the centre and normal Watson–Crick at
both ends. Chain A is on the left and chain B on the right. A dyad axis is present at the centre approximately in the plane of the drawing.
